| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.95(B) |
| Last
Volume: |
875,937 |
Avg
Vol: |
1,084,799 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
8,699 |
11,368 |
11,368 |
11,368 |
| Total Sell Value |
$136,292 |
$185,375 |
$185,375 |
$185,375 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
3 |
3 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kulkarni Shashikant |
President of Lab OperationsOff |
• – – |
2022-07-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,152 |
|
25% |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2022-06-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(57) |
18,580 |
|
- |
|
| Sikri Vishal |
President and CCO, Inivata |
• – – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
148,455 |
148,455 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2022-05-18 |
4 |
OE |
$7.27 |
$24,238 |
D/D |
3,334 |
39,111 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-04-28 |
4 |
OE |
$7.52 |
$43,067 |
D/D |
5,727 |
191,548 |
|
- |
|
| Brown Douglas Matthew |
Chief Strategy Officer |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
82,305 |
158,684 |
|
- |
|
| Sholehvar David |
President, Clinical Services |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,864 |
30,864 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
82,305 |
185,821 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-03-08 |
4 |
OE |
$7.52 |
$37,600 |
D/D |
5,000 |
103,516 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-03-07 |
4 |
AS |
$18.29 |
$58,693 |
D/D |
(3,209) |
98,516 |
|
-54% |
|
| Cardoza George |
President & COO, Lab Ops |
• – – |
2022-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(839) |
244,157 |
|
- |
|
| Brown Douglas Matthew |
Chief Strategy Officer |
• – – |
2022-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(867) |
76,379 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(620) |
101,725 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2022-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(137) |
18,637 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,036 |
147,396 |
|
- |
|
| Cardoza George |
President & COO, Lab Ops |
• – – |
2022-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(503) |
244,996 |
|
- |
|
| Brown Douglas Matthew |
Chief Strategy Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
35,030 |
77,246 |
|
- |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
142,457 |
368,051 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(397) |
102,345 |
|
- |
|
| Bonello William |
Chief Financial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,869 |
102,742 |
|
- |
|
| Wallar Gina M |
President, Pharma Services |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,677 |
33,443 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,341 |
18,774 |
|
- |
|
| Mckenzie Kathryn B |
Chief Sustainability/Risk Ofcr |
• – – |
2022-01-11 |
4 |
OE |
$9.07 |
$19,047 |
D/D |
2,100 |
49,361 |
|
- |
|
| Brown Douglas Matthew |
Chief Strategy Officer |
• – – |
2021-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
30,572 |
42,216 |
|
- |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2021-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
152,858 |
225,594 |
|
- |
|
431 Records found
|
|
Page 2 of 18 |
|
|
0.58 (3.94%) 
